Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Cardiology

The Biology of a Heart Attack: Understanding Your Specific Type

At a Glance

A heart attack can be classified by its ECG pattern (STEMI or NSTEMI), its cause (Type 1 or Type 2), and the appearance of the coronary arteries. MINOCA means a heart attack without major blockage and requires further testing to identify the cause.

A heart attack is not a single event that happens the same way for everyone. While the outcome—injury to the heart muscle—is similar, the biological path to that damage varies. Doctors use specific labels like STEMI, NSTEMI, Type 1, and Type 2 to describe what they see on your tests and why the event happened [1][2]. Understanding these terms helps you make sense of your hospital stay and the specific plan for your recovery.

The Presentation: STEMI vs. NSTEMI

These terms describe what your Electrocardiogram (ECG or EKG) looked like when you first arrived at the hospital. They help doctors categorize the electrical pattern of your heart to determine how fast they need to intervene [3].

  • STEMI (ST-Elevation Myocardial Infarction): The ECG shows an “ST elevation,” an electrical pattern often associated with an acutely occluded (blocked) coronary artery [4]. These patients usually require immediate intervention to reopen the vessel [3].
  • NSTEMI (Non-ST-Elevation Myocardial Infarction): The ECG does not show that specific ST elevation, but blood tests confirm a heart injury [1]. While it was once assumed these were always “partial” blockages, we now know that a significant portion (up to 25%) of NSTEMI patients actually have a fully blocked artery that simply didn’t show the classic STEMI pattern on the ECG [5][1].

The Cause: Type 1 vs. Type 2

While STEMI/NSTEMI describes the ECG presentation, Type 1 and Type 2 describe the underlying mechanism—the “why” behind the heart attack [6].

Type 1: Plaque Rupture

This is the “classic” heart attack mechanism. It happens when an unstable plaque (a buildup of fat and cholesterol in the artery wall) ruptures or erodes [2]. This rupture triggers the body to form a blood clot, which blocks the flow of blood [7]. Treatment focuses on reopening the artery (often with a stent) and using antiplatelet medications to prevent future clots [8].

Type 2: Supply and Demand Mismatch

In a Type 2 heart attack, there is no acute atherothrombotic plaque rupture [9]. Instead, the heart muscle is injured because it cannot get enough oxygen to meet its needs, creating a “supply and demand mismatch.” This usually happens because of another severe stressor on the body, such as:

  • Extreme high or low blood pressure [10].
  • Severe anemia (not enough red blood cells to carry oxygen) [11].
  • A dangerously fast or irregular heart rhythm [10].
  • Sepsis or a severe infection [12].

In these cases, the primary goal of treatment is to correct the underlying trigger (like the infection or the anemia). However, your care team will still individualize your treatment, evaluating whether you also have underlying coronary disease that requires statins or antiplatelets [13].

MINOCA: A Working Diagnosis

Sometimes, a patient has clinical signs of a heart attack, but when doctors perform a coronary angiogram, they find arteries that appear clear or have blockages of less than 50% [14]. This is called MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) [15].

It is important to understand that MINOCA is a working diagnosis, not a final answer [14]. It means “we know you had a heart attack, and now we need to find out why.” Potential causes that require further investigation include:

  • Spontaneous Coronary Artery Dissection (SCAD): A tear in the artery wall [16].
  • Coronary Spasm: The artery temporarily clamps shut [17].
  • Microvascular Dysfunction: Problems in the tiny blood vessels that don’t show up on a standard angiogram [18].

To find the true cause of MINOCA, your team may strongly consider a Cardiac MRI [19][20]. This specialized scan, performed when clinically appropriate, can help distinguish a true heart attack from “mimics” like myocarditis [19]. Finding the specific cause is vital because your treating team will individualize your therapy—such as which medications you take and for how long—based on the specific mechanism they discover [21][22].

Common questions in this guide

How are STEMI and NSTEMI different?
STEMI and NSTEMI describe the pattern seen on the first heart tracing, or ECG, rather than the complete cause of the heart attack. STEMI shows ST elevation, while NSTEMI does not show that pattern but has blood-test evidence of heart muscle injury; an NSTEMI can still involve a completely blocked artery.
How does a Type 1 heart attack differ from a Type 2 heart attack?
Type 1 usually starts when plaque in a coronary artery ruptures or erodes and a blood clot blocks blood flow. Type 2 occurs when the heart lacks enough oxygen for its needs because of another severe stress, such as anemia, infection, major blood-pressure changes, or a fast or irregular rhythm.
What does MINOCA mean if my angiogram shows no major blockage?
MINOCA means a person has signs of a heart attack even though the coronary arteries have no blockage or less than 50% narrowing on angiography. It is a working diagnosis, so doctors may investigate causes such as a small-vessel problem, artery spasm, or a tear in an artery wall called SCAD before tailoring treatment.
Why might I need a cardiac MRI after a heart attack?
A cardiac MRI may be considered when the cause of heart injury is unclear, especially after an angiogram shows no major blockage. It can help distinguish a true heart attack from conditions that mimic it, such as myocarditis, and may help guide treatment.
Does the heart attack type determine which medicines I need?
Yes, treatment depends on whether there was a blocked artery, an underlying trigger, or another mechanism. Type 1 heart attacks often involve reopening the artery and antiplatelet medicines, while Type 2 and MINOCA treatment is individualized to the trigger, coronary disease, and test findings.
Can a heart attack have more than one classification?
These labels answer different questions and can be used together: STEMI or NSTEMI describes the ECG pattern, Type 1 or Type 2 describes the mechanism, and MINOCA describes the appearance of the coronary arteries. Your care team uses the combination of findings to determine the likely cause and treatment plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my heart attack classified as a STEMI or an NSTEMI on my ECG, and what did that tell you about the urgency of my treatment?
  2. 2.Did you find evidence of plaque rupture (Type 1) or did a specific trigger like a severe infection cause this Type 2 event?
  3. 3.If my coronary arteries were 'clear' or had less than 50% blockage, was I given a working diagnosis of MINOCA?
  4. 4.When might a Cardiac MRI be considered to help determine the exact cause of my heart injury?
  5. 5.Was there any evidence of spontaneous coronary artery dissection (SCAD) or a spasm in my arteries?
  6. 6.What specific mechanism caused my heart attack, and how does that affect the specific medications I need to take?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    From Q/Non-Q Myocardial Infarction to STEMI/NSTEMI: Why It's Time to Consider Another Simplified Dichotomy; a Narrative Literature Review.

    Avdikos G, Michas G, Smith SW

    Archives of academic emergency medicine 2022; (10(1)) doi:10.22037/aaem.v10i1.1783.

    PMID: 36426169
  2. 2

    Application of the fourth universal definition of myocardial infarction in clinical practice.

    Mair J, Cullen L, Giannitsis E, et al.

    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2020; (25(4)):322-330 doi:10.1080/1354750X.2020.1764108.

    PMID: 32362195
  3. 3

    [Management of acute coronary syndrome without ST-segment elevation].

    Rubini Gimenez M, Thiele H, Pöss J

    Herz 2022; (47(4)):381-392 doi:10.1007/s00059-022-05120-y.

    PMID: 35699750
  4. 4

    Contemporary NSTEMI management: the role of the hospitalist.

    Pollack CV, Amin A, Wang T, et al.

    Hospital practice (1995) 2020; (48(1)):1-11 doi:10.1080/21548331.2020.1701329.

    PMID: 31815570
  5. 5

    Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis.

    Khan AR, Golwala H, Tripathi A, et al.

    European heart journal 2017; (38(41)):3082-3089 doi:10.1093/eurheartj/ehx418.

    PMID: 29020244
  6. 6

    Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury.

    DeFilippis AP, Chapman AR, Mills NL, et al.

    Circulation 2019; (140(20)):1661-1678 doi:10.1161/CIRCULATIONAHA.119.040631.

    PMID: 31416350
  7. 7

    Identification and Management Strategies for Intracoronary High Thrombus Burden in Patients With STEMI: A Practical Experience and Literature Review.

    Feng X, Liu T

    Reviews in cardiovascular medicine 2025; (26(7)):37466 doi:10.31083/RCM37466.

    PMID: 40776951
  8. 8

    Revisiting type 2 myocardial infarction: Unmet clinical needs.

    Palermi A, Saraullo S, Giordano MB, et al.

    Current problems in cardiology 2025; (50(10)):103148 doi:10.1016/j.cpcardiol.2025.103148.

    PMID: 40783170
  9. 9

    Type 2 myocardial infarction: challenges in diagnosis and treatment.

    Chapman AR, Taggart C, Boeddinghaus J, et al.

    European heart journal 2025; (46(6)):504-517 doi:10.1093/eurheartj/ehae803.

    PMID: 39658094
  10. 10

    Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction: A Secondary Analysis of the High-STEACS Cluster Randomized Clinical Trial.

    Bularga A, Taggart C, Mendusic F, et al.

    JAMA network open 2022; (5(7)):e2220162 doi:10.1001/jamanetworkopen.2022.20162.

    PMID: 35816305
  11. 11

    Provoking conditions, management and outcomes of type 2 myocardial infarction and myocardial necrosis.

    Smilowitz NR, Weiss MC, Mauricio R, et al.

    International journal of cardiology 2016; (218()):196-201 doi:10.1016/j.ijcard.2016.05.045.

    PMID: 27236114
  12. 12

    Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.

    Guimarães PO, Leonardi S, Huang Z, et al.

    American heart journal 2018; (196()):28-35 doi:10.1016/j.ahj.2017.10.007.

    PMID: 29421012
  13. 13

    Type 2 Myocardial Infarction: JACC Review Topic of the Week.

    Sandoval Y, Jaffe AS

    Journal of the American College of Cardiology 2019; (73(14)):1846-1860 doi:10.1016/j.jacc.2019.02.018.

    PMID: 30975302
  14. 14

    Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA).

    Occhipinti G, Bucciarelli-Ducci C, Capodanno D

    European heart journal. Acute cardiovascular care 2021; (10(7)):813-822 doi:10.1093/ehjacc/zuab049.

    PMID: 34179954
  15. 15

    MINOCA: a heterogenous group of conditions associated with myocardial damage.

    Singh T, Chapman AR, Dweck MR, et al.

    Heart (British Cardiac Society) 2021; (107(18)):1458-1464 doi:10.1136/heartjnl-2020-318269.

    PMID: 33568434
  16. 16

    Myocardical Infarction with Non-Obstructive Coronary Arteries (MINOCA): pathogenesis, diagnosis and treatment.

    Sucato V, Comparato F, Ortello A, Galassi AR

    Current problems in cardiology 2024; (49(7)):102583 doi:10.1016/j.cpcardiol.2024.102583.

    PMID: 38679151
  17. 17

    Myocardial infarction with non-obstructive coronary arteries (MINOCA).

    Yildiz M, Ashokprabhu N, Shewale A, et al.

    Frontiers in cardiovascular medicine 2022; (9()):1032436 doi:10.3389/fcvm.2022.1032436.

    PMID: 36457805
  18. 18

    Diagnostic Advancements in MINOCA: Do They Translate to a Better Clinical Outcome? A Review of the Literature.

    Bozika M, Apostolos A, Nastouli KM, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(7)) doi:10.3390/medicina62071243.

    PMID: 42512786
  19. 19

    Diagnostic Value of Cardiac Magnetic Resonance Imaging and Intracoronary Optical Coherence Tomography in Patients With a Working Diagnosis of Myocardial Infarction With Non-obstructive Coronary Arteries - A Systematic Review and Meta-analysis.

    Machanahalli Balakrishna A, Ismayl M, Thandra A, et al.

    Current problems in cardiology 2023; (48(6)):101126 doi:10.1016/j.cpcardiol.2022.101126.

    PMID: 35120967
  20. 20

    Cardiac magnetic resonance imaging in myocardial infarction with non-obstructive coronary arteries (MINOCA): current and evolving perspectives.

    Di Leo M, Vasumini N, Maida A, et al.

    Expert review of cardiovascular therapy 2025; (23(12)):765-775 doi:10.1080/14779072.2025.2577397.

    PMID: 41103008
  21. 21

    MINOCA: One Size Fits All? Probably Not-A Review of Etiology, Investigation, and Treatment.

    Herling de Oliveira LL, Correia VM, Nicz PFG, et al.

    Journal of clinical medicine 2022; (11(19)) doi:10.3390/jcm11195497.

    PMID: 36233366
  22. 22

    Myocardial Infarction with Nonobstructive Coronary Arteries.

    Reynolds HR, Smilowitz NR

    Annual review of medicine 2023; (74()):171-188 doi:10.1146/annurev-med-042921-111727.

    PMID: 36179347

This page is for informational purposes only and does not constitute medical advice. Your cardiology team should interpret your ECG, angiogram, and other test results and choose treatment for your specific situation.

Get notified when new evidence is published on acute myocardial infarction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.